More on SRRK

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+5.6% Growth)
- Ratings (10.0 Score)

Upcoming Events

- Earnings (11/18/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Scholar Rock Holding Corp. (NQ:SRRK)
Delayed: 55.41 -0.26 (0.47%)
Prev. Close $55.67  
Open$55.67 
52 Wk High$ 
52 Wk Low$ 
Day High$56.94 
Day Low$54.91 
P/E N/A  
EPS$ 
Volume921,666 

Friends, Peers and Foes (?): OWL, REGN RHHBY (more...)

Sep 11, 2026 06:25 PM FDA approves Scholar Rock's ISEMBYLD for spinal muscular atrophy
Sep 11, 2026 06:25 PM Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
Sep 10, 2026 09:37 AM BMO Capital Reiterates Outperform Rating on Scholar Rock (SRRK)
Sep 8, 2026 07:53 AM H.C. Wainwright Reiterates Buy Rating on Scholar Rock (SRRK)
Sep 2, 2026 08:02 AM Scholar Rock gets FDA fast track for apitegromab in rare muscle disease
Aug 27, 2026 08:00 AM Scholar Rock to Present at Upcoming Investor Conferences
Aug 24, 2026 09:28 AM BMO Capital Reiterates Outperform Rating on Scholar Rock (SRRK)
Aug 21, 2026 09:06 AM Scholar Rock updates apitegromab regulatory status in U.S., Europe, Japan
Aug 21, 2026 09:06 AM Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan
Aug 14, 2026 04:24 PM Form SCHEDULE 13G/A Scholar Rock Holding Filed by: Redmile Group, LLC
View All Articles

Entities mentioned with SRRK

View All Entities